NVS · Healthcare · $269.2B
After-hours $141.62+0.40%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 19 Drug Manufacturers - General peers
Quarterly Revenue Growth
“성장 드라이버(KISQALI·PLUVICTO·Scemblix·LEQVIO 등)가 전 분기 대비 36% 성장하며 2분기에 전체 매출이 다시 플러스”
In the company's words · 2026 2분기 earnings call